Lorenzo Galluzzi, PhD

Galluzzi, Lorenzo

Associate Professor, Cancer Microenvironment and Signaling Program

Language(s) Other than English

  • Italian
  • Spanish
  • French

Educational Background

  • 2008 PhD, Université Paris Sud/Paris XI (Villejuif, FR)
  • 2004 BSc and MSc, Università di Modena e Reggio Emilia (Modena, IT)

Memberships

  • 2019-Present Spanish Group for Cancer Immune-Biotherapy (GETICA)
  • 2017-Present Society for Immunotherapy of Cancer (SITC)
  • 2017-Present American Association for Cancer Research (AACR)
  • 2016-Present European Academy for Tumor Immunology (EATI)
  • 2010-Present European Research Institute for Integrated Cellular Pathology (ERI-ICP)
  • 2018-2019 SITC Cancer Immune Responsiveness Task Force
  • 2017 Radiation Research Society (RRS)

Honors & Awards

  • 2024 Top 2% Scientist (Stanford University)
  • 2023 Highly Cited Researcher in Immunology and Molecular Biology & Genetics (Clarivate Analytics)
  • 2023 Top 2% Scientist (Stanford University)
  • 2022 Highly Cited Researcher in Immunology, Molecular Biology & Genetics and Pharmacology/Toxicology (Clarivate Analytics)
  • 2022 Top 2% Scientist (Stanford University)
  • 2021 Highly Cited Researcher in Immunology, Molecular Biology & Genetics and Pharmacology/Toxicology (Clarivate Analytics)
  • 2021 SITC 2021 Team Science Award, Team Member (SITC)
  • 2021 Immuno-Oncology Distinguished Young Investigator Research Award, 1st Runner Up (IOYIF)
  • 2020 Highly Cited Researcher in Immunology and Molecular Biology & Genetics (Clarivate Analytics)
  • 2019 Highly Cited Researcher in Immunology and Molecular Biology & Genetics (Clarivate Analytics)
  • 2019 Honorary Assistant Professor Adjunct, Yale School of Medicine (New Haven, CT, USA)
  • 2019 Keys to the city of Zocca (Italy)
  • 2018 Highly Cited Researcher across fields (Clarivate Analytics)
  • 2016 Highly Cited Researcher in Biology & Biochemistry (Thompson Reuters)
  • 2016 Honorary Associate Professor, Université Paris Descartes (Paris, France)
  • 2015 Ranked 6th and the youngest amongst 30th top-cited European Scientists (relative to 2007- 2013), http://www.labtimes.org/

People

Research Interests

The current interest of our team is to elucidate the links between cellular pathways of response to stress – including (but not limited to) autophagy, cellular senescence and multiple variants of regulated cell death – and the preservation of organismal homeostasis, with a particular focus on anticancer immunity. More specifically, we are interested in dissecting the complexity of the tumor microenvironment with respect to the mechanisms through which malignant as well as non-malignant components of the tumor exposed to chemotherapy, radiation therapy and immunotherapy emit danger signals that are involved in the initiation and perpetuation of robust immune responses. The detailed characterization of these molecular and cellular circuitries may identify stress-responsive mechanisms of adaptation in malignant or non-malignant cells as novel targets for the pharmacological manipulation of anticancer immune responses. Ultimately, these findings may translate into novel clinical studies based on combinatorial therapeutic regimens aimed at maximizing immunostimulation within the tumor microenvironment.

Captura-de-pantalla

Ongoing projects

  • Role of the mitochondrial immune checkpoint in the immunogenicity of radiation (Yamazaki et al. Nat Immunol 2020; Rodriguez-Ruiz et al. Oncoimmunology 2019).
  • Mechanisms of resistance to pembrolizumab in HR+ breast cancer (Buque et al. Nat Commun 2020).
  • Synergism between radiation therapy and cell cycle blockade with CDK4/CDK6 inhibitors (Petroni et al. Clin Cancer Res 2021).

Ongoing and prospective collaborations

  • Impact of apoptotic proficiency on the immunogenicity of cell death, in collaboration with Dr. Kristopher A. Sarosiek, Harvard School of Public Health.
  • Impact of metabolic stress on antigen presentation and anticancer immunity, in collaboration with Dr. Laura Santambrogio (Weill Cornell Medical College)
  • (Clement et al. Sci Immunol 2021; Clement et al. Immunity 2021).
  • Impact of serine in colorectal cancer progression and resistance to therapy, in collaboration with Dr. David Montrose, Stony Brook University (Montrose et al.
  • Cancer Res 2021).
  • Impact of systemic metabolism on HR+ mammary carcinogenesis and response to therapy, in collaboration with Dr. Aitziber Buque, Fox Chase Cancer Center and Timothy E. McGraw, Weill Cornell Medical College.

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...